Developmental funding is used at Lombardi for recruitments, bridge funding, investments in new technology and shared resources, and pilot funding for new research projects. Recruitments are critically important to the success of the Lombardi in building its research and clinical care activities. In addltion, innovative and novel components of shared resources have incubated and thrived with the support of Lombardi development strategic investments. Pilot funding has been used to support junior faculty and novel projects; in the next cycle this funding will seed synergy projects to foster Inter- and intra-programmatic research. Developmental funding has been, and will continue to be, a necessary means for completing these essential functions. As evident in Lombardi's past use of the funds, the Cancer Center strives to allocate the funds in equitable and beneficial ways. Since the last review, CCSG developmental funds were leveraged with $41.9 million in institutional funds to recruit four faculty members in areas of strategic need, provide interim salary and research support to one faculty member, support 13 pilot projects and support four new methodologies in shared resources. Funds are now being requested to support three synergy awards per year, funding of biomarker-rich clinical trials testing new hypotheses, provide seed funding for two new shared resources and then additional technologies for existing shared resources, bridge funding for faculty and one or two faculty recruits per year. A portion of funds will be allocated to junior and senior Investigators in development of collaborative translational, basic, and clinical research pilot projects. Lombardi will continue to supplement CCSG developmental funds with Institutional support. We request $280,000 to fund developmental projects over the next funding year. These funds will be a portion of funds allocated to junior and senior investigators in development of collaborative translational, basic, and clinical research pilot projects. $90,000 of CCSG developmental funds will be used to support three pilot synergy studies at $30,000 each, annually. Fundable studies must be proposed by at least two independent Georgetown University faculty members who propose a meritorious and innovative synergistic research study with high likelihood of providing data to support a grant application, e.g., a multi-PI ROI, program project grant, SPORE and center grant. We intend to employ $60,000 of CCSG funds to establish a Survey Methods Shared Resource (SMSR) and a Translational Science Shared Resource (TSSR). $60,000 of CCSG developmental funding will be directed to support the first year of funding for one new recruit yearly, selected as per strategic planning priorities. $40,000 is requested to support pilot funding for one biomarker-rich clinical trial, and $30,000 is requested to provide bridge funding for a CCSG mission-critical investigator.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Georgetown University
United States
Zip Code
Lai, Chih-Hsin; Lai, Ying-Jung J; Chou, Feng-Pai et al. (2016) Matriptase Complexes and Prostasin Complexes with HAI-1 and HAI-2 in Human Milk: Significant Proteolysis in Lactation. PLoS One 11:e0152904
AlHossiny, Midrar; Luo, Linlin; Frazier, William R et al. (2016) Ly6E/K Signaling to TGFβ Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance. Cancer Res 76:3376-86
Chung, Arlene E; Jensen, Roxanne E; Basch, Ethan M (2016) Leveraging Emerging Technologies and the ""Internet of Things"" to Improve the Quality of Cancer Care. J Oncol Pract 12:863-866
Brown, Lindsay; Gutherz, Samuel; Kulick, Catherine et al. (2016) Profile of retigabine-induced neuronal apoptosis in the developing rat brain. Epilepsia 57:660-70
Hunegnaw, Ruth; Vassylyeva, Marina; Dubrovsky, Larisa et al. (2016) Interaction Between HIV-1 Nef and Calnexin: From Modeling to Small Molecule Inhibitors Reversing HIV-Induced Lipid Accumulation. Arterioscler Thromb Vasc Biol 36:1758-71
Taylor, Kathryn L; Hoffman, Richard M; Davis, Kimberly M et al. (2016) Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer. Cancer Epidemiol Biomarkers Prev 25:1240-50
Allen, Megan; Ghosh, Suhasini; Ahern, Gerard P et al. (2016) Protease induced plasticity: matrix metalloproteinase-1 promotes neurostructural changes through activation of protease activated receptor 1. Sci Rep 6:35497
Boca, Simina M; Nishida, Maki; Harris, Michael et al. (2016) Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study. PLoS One 11:e0153461
Spikol, Emma D; Laverriere, Caroline E; Robnett, Maya et al. (2016) Zebrafish Models of Prader-Willi Syndrome: Fast Track to Pharmacotherapeutics. Diseases 4:
Cheema, Amrita K; Maier, Irene; Dowdy, Tyrone et al. (2016) Chemopreventive Metabolites Are Correlated with a Change in Intestinal Microbiota Measured in A-T Mice and Decreased Carcinogenesis. PLoS One 11:e0151190

Showing the most recent 10 out of 883 publications